Endovia Health Sciences, Inc. — Form 8-K
Filed August 31, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Endovia Health Sciences (market cap ~$6.5M) announced it will submit a CannEpil pre-submission conference request to the FDA in the coming week, positioning its CBD/THC cannabinoid formulation for regulated pharmaceutical development. The company welcomed the federal government's support for rescheduling marijuana from Schedule I to Schedule III during DEA proceedings, viewing it as removing historical impediments to cannabinoid research. Endovia is concurrently evaluating additional cannabinoid formulations and seeking expanded financing to support pipeline development and potential acquisitions.
Why this rating
FDA submission is material for a $6.5M biotech; favorable federal policy shift substantially improves regulatory runway. Financing contingent, specifics absent; moderate execution risk remains.
Tradability signal
NO TRADE
No trade: price $0.47 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.47 | +10 min · unknown $0.47 ▲ 0.00% | +30 min · unknown $0.47 ▲ 0.00% | +1 hr · unknown $0.47 ▲ 0.00% | +4 hrs · unknown $0.47 ▲ 0.00% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.